Regulacje i polityka gospodarcza · 29/10/2002

Prospective Grant of Exclusive License: “Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers” U.S. Patent 6,152,430, Issued November 28, 2000, and “Mesothelium antigen and methods and kits for targeting it” U.S. Patent 6,083,502, Issued July 4, 2000

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7(a)(1) (i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the inventions embodied in U.S. Patent 6,153,430: "Nucleic acid encoding Mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers" issued November 28th, 2000, and U.S. Patent 6,083,502: "Mesothelium antigen and methods and kits for targeting it" issued July 4th, 2000, to Cell Genesys, Inc., which is located in Foster City, California. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive license territory will be worldwide and the field of use may be limited to human gene therapy using peptides or antibody fragments for the treatment of cancer.